On March 17, 2026 Verismo Therapeutics, a clinical-stage immuno-oncology company developing a novel multi-chain KIR-CAR platform technology, reported its participation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which will be held April 17-22 in San Diego, California. The company will present new clinical, preclinical, and translational KIR-CAR data in three separate presentations, supporting the advancement of Verismo’s lead pipeline candidates, SynKIR-110 for patients with advanced mesothelin-expressing solid tumors, such as ovarian cancer, mesothelioma, and cholangiocarcinoma, and SynKIR-310 for patients with relapsed or refractory B cell non-Hodgkin lymphomas, as well as preclinical data from University of Pennsylvania collaborators reporting on a novel EGFR-targeted multi-chain KIR-CAR for treatment of glioblastomas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These presentations at AACR (Free AACR Whitepaper) 2026 mark a defining moment in immuno-oncology as we transition from compelling preclinical evidence to first-in-human clinical data from our two lead KIR-CAR-based therapies," said Laura A. Johnson, Ph.D., Chief Scientific Officer and Chief Operating Officer at Verismo Therapeutics. "By moving beyond ‘always-on’ single-chain CAR T to multi-chain KIR-CAR science, we believe we may have the potential to overcome current CAR T therapy limitations to successfully treat patients with solid tumors and to improve clinical responses in patients with blood cancers."
Verismo’s presentations will include:
First clinical data to be released on SynKIR-110 KIR-CAR Phase 1 clinical trial for patients with advanced ovarian cancer, mesothelioma, or cholangiocarcinoma
An oral late-breaking presentation, highlighting the initial clinical results of SynKIR-110 multi-chain KIR-CAR T cell product investigated in STAR-101 Phase 1 Clinical Trial (NCT05568680)
Location: San Diego Convention Center
Abstract Presentation Number: CT104
Presentation Title: Initial results of a first-in-human dose-escalation study of KIR-CAR in patients with advanced mesothelin-expressing solid tumors
Presenting Author: Lead Clinical Investigator Janos L. Tanyi, M.D., Ph.D., Perelman School of Medicine at the University of Pennsylvania
Session Title: Clinical Trials Plenary 3: Cellular Therapies and Complex Immunotherapies
Session Time: 4/20/2026 10:15 AM – 12:15 PM PT
Preclinical and early clinical data to be released on SynKIR-310 for B cell Non-Hodgkin Lymphomas
A poster presentation, highlighting the preclinical data and early clinical data from SynKIR-310 KIR-CAR T cell product investigated in CELESTIAL-301 Phase 1 Clinical Trial (NCT06544265)
Location: San Diego Convention Center, Poster Section 40
Poster Board Number: 11
Poster Number: 5193
Title: Novel SynKIR-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B cell non-Hodgkin lymphoma xenograft mice and shows early clinical signal
Presenting Author: Megan Blair, Ph.D., Verismo Therapeutics
Session Category: Clinical Research
Session Title: Adoptive Cell Therapy 2
Session Time: 4/21/2026 9:00 AM – 12:00 PM PT
First preclinical data to be released on EGFR-targeted multi-chain KIR-CAR T for Glioblastoma
A late-breaking poster presentation, highlighting preclinical data of EGFR-targeted KIR-CAR T cells supporting clinical translation
Location: San Diego Convention Center, Poster Section 53
Poster Board Number: 3
Abstract Presentation Number: LB138
Title: Natural killer cell-based signaling in EGFR-targeted KIR-CAR T overcomes CD3-based CAR T functional deficits to eliminate resistant glioblastomas in vivo
Presenting Author: Jun Xu, Ph.D., Verismo Therapeutics
Session Title: Late-Breaking Research: Immunology 2
Session Time: 4/20/2026 9:00 AM – 12:00 PM PT
(Press release, Verismo Therapeutics, MAR 17, 2026, View Source;including-initial-clinical-trial-results-for-lead-immuno-oncology-candidates-synkir-110-and-synkir-310–at-aacr-annual-meeting-2026-302716606.html [SID1234663633])